Подписаться
Rohit Loomba, MD, MHSc
Rohit Loomba, MD, MHSc
Подтвержден адрес электронной почты в домене ucsd.edu - Главная страница
Название
Процитировано
Процитировано
Год
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
M Eslam, AJ Sanyal, J George, A Sanyal, B Neuschwander-Tetri, ...
Gastroenterology 158 (7), 1999-2014. e1, 2020
23902020
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
BA Neuschwander-Tetri, R Loomba, AJ Sanyal, JE Lavine, ML Van Natta, ...
The Lancet 385 (9972), 956-965, 2015
23852015
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
C Estes, H Razavi, R Loomba, Z Younossi, AJ Sanyal
Hepatology 67 (1), 123-133, 2018
19642018
The global NAFLD epidemic
R Loomba, AJ Sanyal
Nature reviews Gastroenterology & hepatology 10 (11), 686-690, 2013
19582013
Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies
S Singh, AM Allen, Z Wang, LJ Prokop, MH Murad, R Loomba
Clinical gastroenterology and hepatology 13 (4), 643-654. e9, 2015
17092015
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta‐analysis
PS Dulai, S Singh, J Patel, M Soni, LJ Prokop, Z Younossi, G Sebastiani, ...
Hepatology 65 (5), 1557-1565, 2017
16262017
Modeling nafld disease burden in china, france, germany, italy, japan, spain, united kingdom, and united states for the period 2016–2030
C Estes, QM Anstee, MT Arias-Loste, H Bantel, S Bellentani, J Caballeria, ...
Journal of hepatology 69 (4), 896-904, 2018
14872018
Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with …
P Zhang, L Zhu, J Cai, F Lei, JJ Qin, J Xie, YM Liu, YC Zhao, X Huang, ...
Circulation research 126 (12), 1671-1681, 2020
12922020
Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease
L Castera, M Friedrich-Rust, R Loomba
Gastroenterology 156 (5), 1264-1281. e4, 2019
11562019
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
DQ Huang, HB El-Serag, R Loomba
Nature reviews Gastroenterology & hepatology 18 (4), 223-238, 2021
10812021
The gut–liver axis and the intersection with the microbiome
A Tripathi, J Debelius, DA Brenner, M Karin, R Loomba, B Schnabl, ...
Nature reviews Gastroenterology & hepatology 15 (7), 397-411, 2018
10612018
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ...
The Lancet 394 (10215), 2184-2196, 2019
10292019
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
ME Rinella, JV Lazarus, V Ratziu, SM Francque, AJ Sanyal, F Kanwal, ...
Hepatology 78 (6), 1966-1986, 2023
8992023
Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis
R Khera, MH Murad, AK Chandar, PS Dulai, Z Wang, LJ Prokop, ...
Jama 315 (22), 2424-2434, 2016
8842016
Mechanisms and disease consequences of nonalcoholic fatty liver disease
R Loomba, SL Friedman, GI Shulman
Cell 184 (10), 2537-2564, 2021
8822021
Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease
R Loomba, V Seguritan, W Li, T Long, N Klitgord, A Bhatt, PS Dulai, ...
Cell metabolism 25 (5), 1054-1062. e5, 2017
8742017
A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
SL Friedman, V Ratziu, SA Harrison, MF Abdelmalek, GP Aithal, ...
Hepatology 67 (5), 1754-1767, 2018
6922018
Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty …
CC Park, P Nguyen, C Hernandez, R Bettencourt, K Ramirez, L Fortney, ...
Gastroenterology 152 (3), 598-607. e2, 2017
6672017
Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy
R Loomba, A Rowley, R Wesley, TJ Liang, JH Hoofnagle, F Pucino, ...
Annals of internal medicine 148 (7), 519-528, 2008
6442008
Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials
M Noureddin, J Lam, MR Peterson, M Middleton, G Hamilton, TA Le, ...
Hepatology 58 (6), 1930-1940, 2013
5622013
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20